If you or a loved one is taking Tysabri, you may be worried about the rare but serious risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established that PML risk increases with longer treatment duration and certain patient factors. This page outlines the typical timeline of PML development, key symptoms to watch for, and essential questions to discuss with your neurologist.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in New York who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. The prescribing information for Tysabri contains a boxed warning stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing reports. Three specific risk factors for PML have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.
The clinical presentation of PML can include progressive neurological deficits such as weakness, vision changes, speech difficulties, and cognitive decline. Diagnosis typically involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The label instructs healthcare professionals to 'monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML' and to 'withhold TYSABRI immediately at the first sign or symptom suggestive of PML' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these precautions, PML can still occur, and the outcome is often severe disability or death. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing JC virus to reactivate and cause lytic infection of oligodendrocytes. This immunosuppressive effect is the basis for both its therapeutic benefit in multiple sclerosis and its risk of PML.
Regarding the adequacy of warnings, the label includes a boxed warning and requires enrollment in the TOUCH Prescribing Program, which mandates that patients read a Medication Guide and sign an enrollment form acknowledging risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients and their families may argue that the warnings were insufficient or that the risk was not adequately communicated, particularly for those who developed PML despite having no identified risk factors. For settlement-related considerations, affected patients in New York must be aware of the statute of limitations for filing a claim. In New York, the statute of limitations for personal injury actions is generally three years from the date of injury. For medical malpractice or product liability claims related to Tysabri and PML, the clock typically starts when the injury is discovered or reasonably should have been discovered. This 'discovery rule' is important because PML symptoms may develop gradually, and the diagnosis may not be confirmed until weeks or months after initial symptoms. The timeline between exposure and documented harm can vary; PML has been reported after a few months to several years of Tysabri treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients should document the date of first symptoms, the date of PML diagnosis, and all medical records to establish the timeline.
Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadline for their specific case. The statute of limitations may be affected by factors such as the patient's age, mental capacity, and whether the claim is against the manufacturer or a healthcare provider. Settlement amounts in Tysabri PML cases have varied based on the severity of disability, medical expenses, lost income, and other damages. In summary, the medical evidence clearly establishes that Tysabri increases the risk of PML, with identified risk factors and a requirement for monitoring. For New York patients who have suffered PML, the statute of limitations is a critical legal consideration that depends on when the injury was discovered. Prompt legal consultation is advisable to preserve the right to seek compensation. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In New York, the statute of limitations for personal injury actions is generally three years from the date of injury. For Tysabri-related PML claims, the clock typically starts when the injury is discovered or reasonably should have been discovered, known as the 'discovery rule.' Patients should document the date of first symptoms and diagnosis to establish the timeline.
Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.